The GLP is committed to full transparency. Download and review our Annual Report.

Fighting depression: Nasal-based ketamine spray clears key FDA hurdle

| | February 15, 2019

One of the largest hurdles to ketamine becoming a mainstream depression treatment may have just been cleared.

On [February 12], an independent expert panel convened by the Food and Drug Administration discussed whether a nasal spray version of the drug developed by Johnson & Johnson should be approved by the FDA. In a majority vote, they agreed that the drug’s benefits outweighed its risks in treating cases of depression that haven’t responded to other treatments, though not without some conditions. The vote all but signals the drug’s eventual approval, since the FDA rarely strays from these decisions.

What’s made ketamine so enticing as an antidepressant is that its effects in boosting mood seem to happen within hours or even minutes, while other antidepressants can take weeks to work. That rapid action is especially important for people in middle of an immediate crisis who are struggling with suicidal ideation.

Related article:  US researchers moving abroad to avoid FDA's CRISPR-edited animal regulations

J&J’s version is based on the chemically similar esketamine. Esketamine, Johnson & Johnson hoped, would cause fewer side-effects like sedation or dissociation while still providing a similar antidepressant effect.

Read full, original post: A Ketamine-Based Nasal Spray for Depression Could Soon be Approved by the FDA

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend